IMGN Company Profile and Key Details
ImmunoGen, Inc.
IMGN Stock Price Chart
Stock Price Today
ImmunoGen, Inc. (IMGN) stock surged +0.02%, trading at $31.24 on NASDAQ, up from the previous close of $31.23. The stock opened at $31.24, fluctuating between $31.22 and $31.25 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Company Information
| Employees | 277 |
| Beta | 1.17 |
| Sales or Revenue | $108.78M |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
ImmunoGen, Inc. (NASDAQ: IMGN) stock price is $31.24 in the last trading session. During the trading session, IMGN stock reached the peak price of $31.25 while $31.22 was the lowest point it dropped to. The percentage change in IMGN stock occurred in the recent session was 0.02% while the dollar amount for the price change in IMGN stock was $0.01.
The NASDAQ listed IMGN is part of Biotechnology industry that operates in the broader Healthcare sector. ImmunoGen, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Susan Altschuller Ph.D.
Senior Vice President & Chief Financial Officer
Mr. Daniel S. Char J.D.
Senior Vice President, Chief Legal Officer & Sec.
Mr. Joseph J. Kenny
Vice President, Acting Gen. Counsel, Intellectual Property & Sec.
Ms. Renee Lentini
Interim Chief Financial Officer, Vice President of Fin. & Chief Accounting Officer
Dr. Mary Margaret Huizinga FACP, M.D., M.P.H.
Senior Vice President & Head of Medical Affairs
Dr. Susan Altschuller Ph.D.
Senior Vice President & Chief Financial Officer (Leave of Absence)
Dr. Massimo Radaelli M.B.A., Ph.D.
Senior Vice President & GM of International
Mr. Mark Joseph Enyedy
Pres, Chief Executive Officer & Director
Dr. Anna Berkenblit M.D., MM.Sc
Senior Vice President & Chief Medical Officer
Ms. Stacy A. Coen
Senior Vice President & Chief Bus. Officer
Dr. Michael J. Vasconcelles M.D., Ph.D.
Executive Vice President of Research, Devel. & Medical Affairs
Ms. Courtney O'Konek
Senior Director of Corporation Communications & Investor Relations
Ms. Audrey Bergan
Senior Vice President & Chief HR Officer
Dr. Theresa G. Wingrove
Senior Vice President of Regulatory Affairs & Quality
Anabel Chan
Head of Investor Relations
IMGN's closing price is 765.24% higher than its 52-week low of $3.61 where as its distance from 52-week high of $31.25 is -0.05%.
Number of IMGN employees currently stands at 277.
Official Website of IMGN is: https://www.immunogen.com
IMGN could be contacted at phone 781 895 0600 and can also be accessed through its website. IMGN operates from 830 Winter Street, Waltham, MA 02451-1477, United States.
IMGN stock volume for the day was 19.31M shares. The average number of IMGN shares traded daily for last 3 months was 8.29M.
The market value of IMGN currently stands at $8.73B with its latest stock price at $31.24 and 279.35M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com